Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MemAP: Memantine to Reduce Antipsychotics in Alzheimer's Dementia
NCT00649220Phase 4Terminated
- Sponsor
- Merz
- Start
- Jul 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of memantine in Alzheimer's disease (AD), sponsored by Merz. Primary endpoint: Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD). Started Jul 2008; status: terminated.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00649220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00649220.